Tech IPOs, public-market debuts, and what each one means for the exit environment.
Value Add Pulse compared the 2026 US listing tally with 2025 and found slightly fewer deals despite record-sized offerings, a mix shift toward large asset-heavy issuers rather than a broad reopening.
Four small-cap S-1 filings landed September 10-11: an Alberta oil-and-gas shell, a Malaysian iron-ore resale registration, and two blank-check SPACs targeting a combined roughly $175 million, none tied to venture-scale operating businesses.
Markets repriced the AI trade along a single fault line after Dario Amodei's pacing essay: semiconductor names fell hard while Alphabet, Microsoft and Meta gained.
Holtec Nuclear, Bamboo Insurance and Electra Therapeutics set IPO terms within a day of each other, lining up roughly $1.8 billion of supply; with Orion180's $320 million deal, the week's calendar totals about $2.1 billion.
The 10-year Treasury yield touched 5% for the first time since 2023 and Brent crude rose to about $107 after a Saudi pipeline shutdown, with traders pricing an 88% chance of a Fed hike Wednesday.
Sam Altman told Fortune an OpenAI IPO in 2026 would be an "ill-advised moment" given AI safety concerns, ruling out a listing this year as the company still targets a $1 trillion valuation.
Six S-1 and S-1/A filings hit the SEC in a single two-day window -- most of them blank-check shells and one crypto ETF -- continuing 2026's pattern of a busy pipeline dominated by speculative vehicles.
Rent the Runway filed a new S-1 for a $15 million rights offering to existing shareholders, days after taking on more debt and settling a securities class action for $9 million.
SEEQC, a quantum-computing chip infrastructure maker, amended its S-1 as its Nasdaq listing via a merger with blank-check company Allegro Merger Corp moves closer to closing.
Eloxx Pharmaceuticals filed an S-1 to uplist from the OTC Pink market to Nasdaq, offering 2.73 million shares plus pre-funded warrants at an assumed $10-12 per share to fund its rare-kidney-disease drug candidate.
Renaissance Capital shows no US IPO pricings for the week of September 7 -- but 2026's full-year filing pace, and a well-worn September seasonality pattern, say the window is still wide open.
AI data-center startup Nscale added former OpenAI executive Fidji Simo to its board ahead of a fall IPO targeting a $25 billion valuation, well above its $14.6 billion private mark.
The two largest pending tech listings -- a $60B+ Anthropic offering and a $16B Oura float -- have each slipped their original timelines, with Anthropic's roadshow now pointing to mid-October.
The National Stock Exchange of India set a price band targeting a $55 billion valuation, positioning its listing to become India's largest-ever IPO.
Holtec Nuclear priced a $15-$18 range for its Nasdaq IPO, seeking up to $900 million and a valuation as high as $10.2 billion, as the SMR and spent-fuel company rides the same power crunch driving AI data-center demand.
Tencent-backed AI chipmaker Enflame nearly tripled on its Shanghai STAR Market debut, the latest Chinese Nvidia challenger to surge as Beijing pushes for semiconductor self-sufficiency.
Enflame, the last of China's four state-backed AI chipmakers to go public, raised $911 million and then saw its shares surge as much as 206% on its Shanghai STAR Market debut, without ever reporting a profit.
Five blank-check companies filed IPO papers within days of each other in early September, two of them sequels from sponsors whose first vehicles haven't even found a target -- a pattern that says more about fee economics than a startup wave.
MapLight Therapeutics filed a $150 million follow-on just eleven months after its own IPO, part of a broader 2026 pattern of newly public biotechs returning to capital markets well ahead of their first pivotal data readouts.
Polymarket named former Amazon finance chief Warren Jenson as its first-ever CFO, a governance milestone as the prediction market tries to close ground on regulated rival Kalshi.
DeepSeek has engaged CITIC Securities to prepare a Shanghai STAR Market listing, with a pre-IPO financing round reportedly valuing the AI lab at roughly $74.5 billion before new capital is raised.
Hometown Financial Group, parent of bankESB, bankHometown and TruNorth Bank, filed a $600 million Nasdaq IPO at a fixed $10 per share to fund its acquisition of New Hampshire's Primary Bank and convert from mutual to stock ownership.
Pulse has tracked 60 IPO-pipeline stories in the first nine days of September alone, on pace to roughly match August -- but a growing share of any given week's S-1 batch is blank-check shells rather than operating companies.
Orion180 Insurance Group set terms for its Nasdaq IPO at $15 to $17 per share for 20 million shares, targeting roughly $320 million at the midpoint, three weeks after first filing its S-1 for the specialty home insurer.
Most of the S-1 filings Pulse has tracked this week register existing shares for resale under debt or warrant agreements rather than take a new company public, a distinction that matters for anyone reading filing volume as IPO-market health.
Anthropic pushed its public IPO prospectus to late September and its roadshow to no earlier than mid-October, an adjustment that says more about this fall's crowded IPO calendar than about Anthropic itself.
2026's IPO market is running roughly flat with 2025's pace by deal count, but the pipeline is increasingly bifurcated between mega-cap AI listings and a steady drip of microcap S-1 filings with little institutional demand.
StableCoinX filed an amended S-1 disclosing it now holds roughly 3.03 billion ENA tokens, about 20% of total supply, making it the largest corporate holder of Ethena's governance token.
Two of the three companies Pulse tracked in an early-September S-1 batch, AIxCrypto Holdings and Laser Photonics, filed amended registration statements this week, a routine sign the SEC sent comment letters before either can price.
MapLight Therapeutics, which IPO'd on Nasdaq in October 2025, filed a new S-1 for a $150 million follow-on financing ahead of Phase 2 schizophrenia data expected later this year.
SOBR Safe filed registration paperwork for its Nasdaq-saving business combination with hydrogen technology company Clean World Ventures, needing the deal closed by September 15 or facing delisting.
Three unrelated issuers -- an insurer, a laser-equipment maker, and an AI-crypto microcap -- had S-1/A amendments become public the same day, with only Orion180 disclosing an actual IPO price range.
This week's SEC EDGAR docket shows roughly a dozen S-1 and S-1/A filings, nearly all from small or micro-cap issuers, alongside continued waiting for the next round of megacap technology listings.
Five separate blank-check acquisition companies filed S-1 registration statements within days of each other in early September, including two sequels from sponsors whose earlier SPACs already completed their own IPOs.
Holtec's priced IPO and SB Energy's hyperscaler-backed backlog both sell the same underlying thesis -- that data centers will pay a premium for firm power -- and public investors are about to test whether that premium is real.
Holtec's IPO is priced off physical assets it already owns and operates; SB Energy's is priced off a $439 billion contract backlog against $269 million of current revenue -- two structurally different bets inside the same AI-power IPO wave.
Evolution Metals & Technologies, a critical-materials rollup, and Ocean Power Technologies, a marine-energy developer, both filed new S-1 registrations tied to existing debt and warrant structures rather than fresh public listings.
Holtec's priced IPO shared EDGAR's docket Tuesday with two smaller, unnoticed filers -- Evolution Metals & Technologies and Ocean Power Technologies -- a reminder the pipeline is wider than the handful of names anyone tracks.
CDT Equity, a Nasdaq-listed biopharma formerly known as Conduit Pharmaceuticals, and Securetech Innovations, an OTC-listed technology holding company, both filed new S-1 registrations the same day.
Three blank-check sponsors filed or amended registrations this week -- New Iceland Arctic, Legion Capital and Albatross Acquisition Corp -- each betting the 2027 listing window opens wider than 2026's has.
Oura's S-1 shows 74% revenue growth, an actual net profit, and 5 million paid members -- a financial profile most of 2026's IPO hopefuls, including the AI labs, cannot come close to matching.
Acurx Pharmaceuticals, a Nasdaq-listed antibiotic developer trading as ACXP, filed a new S-1 that continues a 2026 pattern of small registered-direct offerings rather than a first-time listing.
The US has logged 238 IPOs in 2026 as of September 7, modestly ahead of 2025's pace -- a quiet, broad-based record overshadowed by the handful of megacap AI listings everyone is actually watching.
Rothe Development, a Webster, Texas NASA and defense-services contractor founded in 1967, filed an S-1 seeking up to $50 million in an IPO after generating $122 million of revenue over the past year.
Holtec Nuclear set terms for its Nasdaq IPO -- 50 million shares at $15 to $18, raising up to $900 million at a valuation near $10.2 billion -- moving the SMR and spent-fuel company from filed to priced.
Seven companies dominate 2026's IPO chatter, but only two -- Oura and SB Energy -- have an actual filing on record; the rest range from retained bankers to a CEO's public comment.
Anthropic is pushing its planned IPO back to mid-October while it finalizes a $15 billion revolving credit line, timing a listing that could raise $75 billion or more days ahead of the US midterms.
US markets are shut for Labor Day and the SEC filing tape has been empty since Friday, which puts the year's most concentrated IPO stretch -- the eight weeks after the holiday -- starting tomorrow with one AI-adjacent name actually on file.
US listings are running at their highest count since 2021, but SpaceX and Cerebras alone likely raised more than the other 236 deals combined -- a count recovery without a depth recovery.
Cerebras opened at $350 against a $185 price in May and is back at that offer price in September, which makes it the only completed public-market experiment in how AI compute businesses get valued after the narrative premium wears off.
The same handful of banks are simultaneously leading Anthropic's, Oura's and SB Energy's mega-IPOs, and staffing capacity at the top underwriters may be constraining 2026's listing calendar more than investor demand.
Nscale is reportedly in talks for $3.5 billion in pre-IPO financing, joining Anthropic's credit facility and Oura's early-investor cash-outs as evidence the line between late-stage private and public capital is blurring.
New blank-check filings have kept a steady trickle through 2026 even as traditional IPO volume barely outpaces 2025, a sentiment signal Pulse has tracked since two SPAC-related filing waves earlier this year.
Authors say publishers and literary agents are claiming shares of Anthropic's $1.5 billion copyright settlement they may not be owed, turning a closed liability into an open administrative dispute.
Registration activity continued through September 5 and 6 with a mix of small-cap resale filings and defense and med-tech names, extending the pattern Pulse tracked earlier in the week of amendments outnumbering genuinely new offerings.
Nvidia is now an investor in three companies preparing to list that will spend much of their raised capital buying Nvidia systems, and the disclosures make revenue quality harder to judge, not easier.
Despite headline-grabbing megadeals in the pipeline, the total count of US IPOs in 2026 is running only marginally ahead of 2025's pace, suggesting mega-round enthusiasm hasn't yet translated into broad listing volume.
Oura's filing shows $1.21 billion of revenue in nine months and about 5 million paid members, but Ultrahuman, RingConn, Circular and Samsung are all shipping hardware into the category it created.
The Nasdaq-listed defense roll-up, formerly known as Nukkleus, filed a new S-1 as it keeps acquiring Israeli drone, AI-software and munitions-component suppliers into a holding structure built around Tier 2/3 defense programs.
Anthropic's public S-1 filing has moved to late September and its investor roadshow to mid-October at the earliest, pushing a listing that could value the company at up to $2 trillion to just days before the November midterm elections.
